RBC Capital on Arrowhead Pharma (ARWR): 'SRPT Deal Closed; Focus Now Sharpened to Cardiometabolic'
Tweet Send to a Friend
RBC Capital analyst Luca Issi reiterated an Outperform rating and $42.00 price target on Arrowhead Pharma (NASDAQ: ARWR).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
